Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
At the heart of new antidiabetic agents lies hope for delaying the onset of CVD
+Print Archive
Pathology Update
At the heart of new antidiabetic agents lies hope for delaying the onset of CVD
Wednesday 22 May 2019, 07:00 AM

More change is ahead in diabetes treatment, including improving cardiovascular outcomes for more patients, says Australian expert Jonathan Shaw
The fifth and final article in a series from Pathology Update 2019, this year’s conference of the Royal College of Pathologists of Australasia. Virginia McMillan attended as a guest of the college
Glycaemic targets may be relaxed. If a drug will reduce cardiovascular and renal risk, “what is the point of pushing HbA1c from above 7.5 per cent to
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMoa1504720
5. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347-357. DOI: 10.1056/NEJMoa1812389